Cumberland Pharmaceuticals

Intravenous Ibuprofen (internal code 2011_436) is a small-molecule nonsteroidal anti-inflammatory drug (NSAID) developed by Cumberland Pharmaceuticals Inc for the indication of obesity. The program has reached approved status as of the latest milestone dated 2015-09-03. Ibuprofen is a well-established active pharmaceutical ingredient with extensive regulatory approval globally; however, the intravenous formulation represents a distinct therapeutic approach. The mechanism of action and specific target for this obesity indication are not yet disclosed. Cumberland Pharmaceuticals' strategy appears focused on repurposing an established NSAID via an alternative route of administration to address obesity management. The program is associated with clinical trial NCT01707251. Regulatory approval has been achieved in multiple jurisdictions including the United States, European Union, and Australia, though the specific approval pathway and date for the intravenous obesity indication require further clarification. The program status is marked as completed, indicating that active development activities have concluded.

Obesity represents a significant unmet medical need with substantial disease burden and limited pharmacological treatment options. The prevalence of obesity continues to rise globally, creating substantial market opportunity for novel therapeutic approaches. Repurposing established anti-inflammatory agents via alternative routes of administration may offer a differentiated mechanism compared to existing obesity therapeutics, potentially addressing metabolic and inflammatory components of the disease. The competitive landscape for obesity treatment includes multiple approved agents, though mechanistic diversity remains limited. Cumberland Pharmaceuticals' development of an intravenous ibuprofen formulation for obesity suggests exploration of anti-inflammatory pathways in weight management, an area of growing scientific interest. The commercial significance is substantial given the large patient population with obesity and the limited number of approved pharmacological interventions. Success in this indication could establish a new therapeutic category and generate meaningful revenue in a high-prevalence disease area. The program's completion and approved status indicate regulatory acceptance of the approach, though market penetration and clinical adoption will depend on comparative efficacy, safety profile, and positioning relative to existing therapies.

Drug Class: Nonsteroidal anti-inflammatory drug (NSAID)

Active Pharmaceutical Ingredient: Ibuprofen

Modality: Small molecule

Route of Administration: Intravenous (note: the referenced brand APO-IBUPROFEN 400 is an oral formulation; the intravenous formulation for obesity is the subject of this program)

Mechanism of Action: Not yet disclosed for the obesity indication

Target: Not yet disclosed

Therapeutic Class: Cardiovascular system (C01) per regulatory classification, though indication is obesity

Related Therapies: Ibuprofen is available in multiple formulations and routes globally, with extensive generic competition. Oral ibuprofen is available from numerous manufacturers including Apotex, Viatris, Wagner Pharmaceuticals (Australia), and many others across the United States and Europe.

First Approval: Ibuprofen as an active ingredient has been approved for decades; specific approval date for the intravenous obesity formulation is not yet disclosed

Patent Status: Not yet disclosed

United States: Ibuprofen is approved via multiple ANDA and NDA applications (over 200 application numbers listed). Cumberland Pharmaceuticals is listed among US sponsors. Specific approval status for the intravenous obesity formulation is not yet disclosed.

European Union: Ibuprofen is approved with multiple marketing authorization holders including Gen.Orph, Recordati Rare Diseases, and Wyeth Consumer Healthcare. EMA product numbers include EMEA/H/C/000549, EMEA/H/C/001108, and EMEA/H/C/006129. Authorization dates range from 2009 to 2026. Specific approval for the intravenous obesity indication is not yet disclosed.

Australia: Ibuprofen is approved with PBS codes 3190X, 3192B, 5123P, 5124Q, 5368M. Sponsors include Apotex Pty Ltd, Viatris Pty Ltd, and Wagner Pharmaceuticals Pty Ltd. First listed dates range from 2006 to 2024. Specific approval for the intravenous obesity formulation is not yet disclosed.

Japan (PMDA) and China (NMPA): Regulatory status not yet disclosed.

Overall Status: The program is marked as approved with completion status as of 2015-09-03, though specific regulatory approval details for the intravenous obesity indication remain not yet disclosed.

Strategic Implications: Cumberland Pharmaceuticals' development of intravenous ibuprofen for obesity represents a repurposing strategy leveraging an established, well-tolerated NSAID. The intravenous route may enable rapid onset and intensive management in acute obesity-related conditions or specialized clinical settings. The program's completion and approved status by 2015 suggests successful regulatory navigation, though market adoption and clinical utility remain to be established.

Competitive Implications: The anti-inflammatory mechanism offers potential differentiation from existing obesity therapeutics, which typically target appetite regulation or energy expenditure. However, competitive positioning depends on comparative efficacy, safety durability, and clinical outcomes data not yet disclosed. The crowded obesity market and limited mechanism diversity present both opportunity and challenge.

Future Catalysts: Publication of clinical trial results from NCT01707251 would provide critical evidence supporting efficacy and safety. Market launch and real-world clinical adoption data would indicate commercial viability. Comparative effectiveness studies versus established obesity medications would clarify competitive positioning. Label expansion or additional indications leveraging the intravenous formulation could broaden market opportunity.

Expected Milestones: No future milestones are disclosed. Commercial availability and market penetration timelines are not yet disclosed. Post-marketing surveillance and safety monitoring data will be important given the chronic nature of obesity treatment and potential long-term NSAID exposure considerations.